Dear BSGCT members
The House of Commons Science and Technology Committee has just released details of a new Inquiry: Leaving the EU: implications and opportunities for science and research, with details below. While many other organizations will be putting in evidence, we would like to coordinate a response from our membership on specific matters related to Gene and Cell Therapy, under the headings below. Please send any responses to firstname.lastname@example.org by Friday 14th July.
Sian Harding, Chair BSGCT Clinical Translation and Regulatory Affairs Subcommittee
The Science and Technology Committee has decided to examine the implications and opportunities of leaving the EU for science and research. The Committee intends to hold hearings on this inquiry during July, and invites written submissions during that period, which might address the following issues:
• What the effect of the various models available for the UK’s future relationship with the EU will be on UK science and research, in terms of:
o Free movement of researchers and students;
o Access to funding
o Access to EU-funded research facilities, both in the UK and abroad
o Intellectual property and commercialisation of research
• What the science and research priorities for the UK Government should be in negotiating a new relationship with the EU.
• What science and technology-related legislation, regulations and projects will need to be reviewed in the run up to the UK leaving the EU.
• The status of researchers, scientists and students working and studying in the UK when the UK leaves the EU, and what protections should be put in place for them.
• The opportunities that the UK’s exit presents for research collaboration and market access with non-EU countries, and how these might compare with existing EU arrangements.
• What other measures the Government should undertake to keep UK science and research on a sound footing, with sufficient funding, after an EU exit.